Document is current
Any future updates will be listed below
-
Authors
Panopoulos, Stylianos https://orcid.org/0000-0002-3720-5996
Tzilas, Vasilios https://orcid.org/0000-0002-7030-6166
Bournia, Vasiliki-Kalliopi https://orcid.org/0000-0002-2162-1362
Tektonidou, Maria G. https://orcid.org/0000-0003-2238-0975
Sfikakis, Petros P. https://orcid.org/0000-0001-5484-2930
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 9 August 2024
First Online: 24 August 2024
Declarations
:
: The study protocol was approved by the ethics committee of Laikon University Hospital (approval number 686/23-06-2011) and all patients gave written informed for their personal data analysis
: S. Panopoulos has received consultant fees and honoraria for lectures from Pfizer, Aenorasis, Amgen, Farmaserv Lilly, and Abbvie; V. Tzilas declares no conflict of interest; V-K Bournia declares no conflict of interest; M. Tektonidou has received consulting fees from El Lilly, GSK, and UCB and unrestricted grants from GSK, Faran, DEMO, Vianex and UCB; P. Sfikakis has received consultant fees from Actelion, Pfizer, Genesis, MSD, UCB, Boehringer Ingelheim, Aenorasis, Farmaserv Lilly, Gilead, Abbvie, and Novartis, and grant/research support from Abbvie, Roche, Pfzer, Faran, Amgen, Jannsen, Boehringer Ingelheim, and Gilead.
